Nuestros investigadores

Eduardo Asín Prieto

Publicaciones científicas más recientes (desde 2010)

Autores: Kirby, Andrew, (Autor de correspondencia); Asín, Eduardo; FA Burns; et al.
Revista: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
ISSN 1435-4373  Vol. 38  Nº 2  2019  págs. 357 - 363
Standard bolus-dosed antibiotic prophylaxis may not inhibit growth of antibiotic resistant colonic bacteria, a cause of SSIs after colorectal surgery. An alternative strategy is continuous administration of antibiotic throughout surgery, maintaining concentrations of antibiotics that inhibit growth of resistant bacteria. This study is a pilot comparing bolus-continuous infusion with bolus-dosed cefuroxime prophylaxis in colorectal surgery. This is a pilot randomised controlled trial in which participants received cefuroxime bolus-infusion (intervention arm) targeting free serum cefuroxime concentrations of 64mg/L, or 1.5g cefuroxime as a bolus dose four-hourly (standard arm). Patients in both arms received metronidazole (500mg intravenously). Eligible participants were adults undergoing colorectal surgery expected to last for over 2h. Results were analysed on an intention-to-treat basis. The study was successfully piloted, with 46% (90/196) of eligible patients recruited and 89% (80/90) of participants completing all components of the protocol. A trialled bolus-continuous dosing regimen was successful in maintaining free serum cefuroxime concentrations of 64mg/L. No serious adverse reactions were identified. Rates of SSIs (superficial and deep SSIs) were lower in the intervention arm than the standard treatment arm (24% (10/42) vs. 30% (13/43)), as were infection within 30days of operation (41% (17/43) vs 51% (22/43)) and urinary tract infections (2% (1/42) vs. 9% (4/43)). Th
Autores: Asín, Eduardo; Parra-Guillen, ZP; et al.
Revista: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
ISSN 0928-0987  Vol. 136  2019 
The liver is a well-known immunotolerogenic environment, which provides the adequate setting for liver infectious pathogens persistence such as the hepatitis B virus (HBV). Consequently, HBV infection can derive in the development of chronic disease in a proportion of the patients. If this situation persists in time, chronic hepatitis B (CHB) would end in cirrhosis, hepatocellular carcinoma and eventually, the death of the patient. It is thought that this immunotolerogenic environment is the result of complex interactions between different elements of the immune system and the viral biology. Therefore, the purpose of this work is to unravel the mechanisms implied in the development of CHB and to design a tool able to help in the study of adequate therapies. Firstly, a conceptual framework with the main components of the immune system and viral dynamics was constructed providing an overall insight on the pathways and interactions implied in this disease. Secondly, a review of the literature was performed in a modular fashion: (i) viral dynamics, (ii) innate immune response, (iii) humoral and (iv) cellular adaptive immune responses and (v) tolerogenic aspects. Finally, the information collected was integrated into a single topological representation that could serve as the plan for the systems pharmacology model architecture. This representation can be considered as the previous unavoidable step to the construction of a quantitative model that could assist in biomarker and target identification, drug design and development, dosing optimization and disease progression analysis.
Autores: Cattrall, J. W. S.; Asín, Eduardo; Freeman, J. ; et al.
Revista: JOURNAL OF PATHOLOGY
ISSN 0022-3417  Vol. 249  Nº Supl. 1  2019  págs. S22 - S22
Autores: Ruiz, María Leire; Asín, Eduardo; Parra-Guillen, ZP; et al.
Revista: CLINICAL CANCER RESEARCH
ISSN 1078-0432  Vol. 24  Nº 14  2018  págs. 3236 - 3238
Pharmacokinetic modeling, traditionally using drug exposure, is widely used to support decision-making in translational medicine and patient care. The development of mechanistic computational models that integrate drug concentrations at the site of action making use of existing knowledge opens a new paradigm in optimal dosing. (C) 2018 AACR.
Autores: Asín, Eduardo; Martín, Salvador; et al.
Revista: JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
ISSN 1567-567X  Vol. 44  Nº Supl. 1  2017  págs. S41 - S42
Autores: Asín, Eduardo; Parra-Guillen, ZP; et al.
Revista: JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
ISSN 1567-567X  Vol. 44  Nº Supl. 1  2017  págs. S30 - S30